Peripheral nerve injuries - Pipeline Insight, 2024

This “Peripheral nerve injuries - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral nerve injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peripheral nerve injuries Understanding

Peripheral nerve injuries: Overview

Peripheral nerve injuries (PNI) include a variety of conditions in which one or more peripheral nerves are damaged. It leads to neurological deficits distal to the level of the lesion present. PNIs affect all age groups and damage to the peripheral nerves is known as peripheral neuropathy. The symptoms of PNI may vary depending on the nerve fiber affected and include pain in the affected area, burning sensations and numbness. The diagnosis of PNI involves a medical history, neurological examination, and, in some cases, diagnostic tests like x-ray if fracture is suspected, CT/MRI, or electrodiagnostic examination. Treatment for PNI depends on the injury and other external factors including early nerve exploration and repair. Nonsurgical treatments include medications, immobilization and physical therapy. Surgical treatment may be needed if the individual has persistent neurologic symptoms.

Peripheral nerve injuries - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral nerve injuries pipeline landscape is provided which includes the disease overview and Peripheral nerve injuries treatment guidelines. The assessment part of the report embraces, in depth Peripheral nerve injuries commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral nerve injuries collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral nerve injuries R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral nerve injuries.

Peripheral nerve injuries Emerging Drugs Chapters

This segment of the Peripheral nerve injuries report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral nerve injuries Emerging Drugs

NTX-001: Neuraptive Therapeutics NTX-001 is a combination drug-device product. NTX-001 has been developed as surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve in the U.S. via the FDA 505 (b) (2) development pathway. In May 2020, Neuraptive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its therapeutic product, NTX-001, for the treatment of patients with peripheral nerve injuries. The drug is in Phase II clinical studies for the treatment of peripheral nerve injuries.

ONO-2910: Ono Pharmaceutical ONO-2910 promotes Schwann cell differentiation and myelination and is expected to improve various symptoms associated with peripheral neuropathy by protecting and promoting regeneration of peripheral nerve cells. The drug is currently under Phase II clinical development for the treatment of Peripheral nerveinjuries.

Peripheral nerve injuries: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral nerve injuries drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral nerve injuries

There are approx. 10+ key companies which are developing the therapies for Peripheral nerve injuries. The companies which have their Peripheral nerve injuries drug candidates in the most advanced stage, i.e. Phase II include, Neuraptive Therapeutics.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Peripheral nerve injuries pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral nerve injuries: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Peripheral nerve injuries therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral nerve injuries drugs.

Peripheral nerve injuries Report Insights

• Peripheral nerve injuries Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peripheral nerve injuries Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peripheral nerve injuries drugs?
• How many Peripheral nerve injuries drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral nerve injuries?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral nerve injuries therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peripheral nerve injuries and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Neuraptive Therapeutics
• MicroCures
• SanBio
• Kanna LifeSciences
• Sonnet BioTherapeutics
• Ono Pharmaceutical
• AxoGen
• Med GenesisTherapeutix
• Tetragenetics

Key Products

• NTX-001
• siFi2
• SB 308
• KLS-13019
• Recombinant IL-6
• ONO-2910
• Avance Nerve Graft
• SON-081
• Liatermin
• TTG-108

This product will be delivered within 2 business days.